Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 25;149(6):dev199858. doi: 10.1242/dev.199858

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

PMC Copyright notice

Fig. 4. — svep1 loss-of-function leads to a defect in tip/stalk cell specification in primary angiogenic sprouts. (A) Maximum intensity projection of a representative TgBAC(apln:eGFP)^bns157, Tg(-0.8flt1:RFP)^hu5333 MO-CTL (5 ng) embryo. A′ shows the unprocessed maximum intensity projection, A″ shows the GFP signal volume-masked by the RFP signal, to limit detection to the endothelium and A‴ shows the resulting endothelial GFP signal only. Panel on right is magnification of boxed area in A″. (B) Maximum intensity projection of a representative TgBAC(apln:eGFP)^bns157, Tg(-0.8flt1:RFP)^hu5333MO-CTL (5 ng) embryo. B′ shows the unprocessed maximum intensity projection, B″ shows the GFP signal volume-masked by the RFP signal, to limit detection to the endothelium and B‴ shows the resulting endothelial GFP signal only. Panel on right is magnification of boxed area in B″. White arrowheads indicate apln:eGFP expression in ISVs in A and B. (C) Maximum intensity projection of a MO-CTL (5 ng) aISV at 48 hpf, highlighting the ventral and dorsal region used for further quantifications in D and E. (D) Quantification of the percentage of aISVs with apln:eGFP-positive endothelial cells in the dorsal and ventral regions in 48 hpf MO-CTL (5 ng) (n=10) and MO-svep1(5 ng) (n=16) morphant embryos treated with 1× (0.014%) tricaine from 30 to 48 hpf (N=3). (E) Quantification of the percentage of aISVs with more than one apln:eGFP-positive endothelial cell in 48 hpf MO-CTL (5 ng) (n=10) and MO-svep1 (5 ng) (n=16) morphant embryos treated with 1× (0.014%) tricaine from 30 to 48 hpf (N=3). (F) Representative image of p-ERK and ERK levels in FACS sorted endothelial cells from MO-CTL (5 ng) and MO-svep1 (5 ng) morphants at 48 hpf treated with 1× (0.014%) tricaine from 30 to 48 hpf (N=4). (G) Quantification of p-ERK in FACS sorted endothelial cells of MO-CTL (5 ng) and MO-svep1 (5 ng) morphants at 48 hpf, treated with 1× (0.014%) tricaine from 30 to 48 hpf. Expression levels were normalised to total ERK levels (N=4). (H) Quantification of the percentage of aISVs with apln:eGFP-positive endothelial cells in the dorsal and ventral regions in 48 hpf embryos treated with 1× (0.014%) (n=22) or 2× (0.028%) (n=24) tricaine from 30 to 48 hpf (N=3). (I) Quantification of the percentage of aISVs with more than one apln:eGFP-positive endothelial cell in 48 hpf embryos treated with 1× (0.014%) (n=22) or 2× (0.028%) (n=24) tricaine from 30 to 48 hpf (N=3). Data are mean±s.d. Mann–Whitney test. Scale bars: 50 μm (A′-A‴,B′-B‴); 10 μm (A,B, magnification, C).